

Accepted Manuscript

Title: Why is Research in Early-Stage Cancer Research so Low?

Author: Vinay Prasad Stephan Lindner

PII: S2213-5383(18)30048-1

DOI: <https://doi.org/doi:10.1016/j.jcpo.2018.07.003>

Reference: JCPO 172



To appear in:

Received date: 16-5-2018

Revised date: 13-7-2018

Accepted date: 22-7-2018

Please cite this article as: Vinay Prasad, Stephan Lindner, Why is Research in Early-Stage Cancer Research so Low?, *Applied Soft Computing Journal* (2018), <https://doi.org/10.1016/j.jcpo.2018.07.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights:

- Technological barriers are one reason why drug development for early-stage solid cancers is low.
- Drug development for blood cancers is comparatively easier.
- Surrogate approvals have little effect on drug development for early-stage solid cancers.

Accepted Manuscript

Download English Version:

<https://daneshyari.com/en/article/8787316>

Download Persian Version:

<https://daneshyari.com/article/8787316>

[Daneshyari.com](https://daneshyari.com)